Please check your internet connection and try again.
# Ecospirin (Aspirin Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and antiplatelet properties. The enteric coating is designed to delay the release of aspirin until it reaches the small intestine, which may reduce gastric irritation.
## Primary Indications
* **Cardiovascular prophylaxis:** Prevention of myocardial infarction and stroke in patients with a history of cardiovascular disease or risk factors.
* **Pain and inflammation:** Management of mild to moderate pain and inflammatory conditions. (Less common use for enteric-coated forms due to slower onset).
* **Kawasaki disease:** Treatment and prevention of coronary artery aneurysms.
## Adult Dosing
* **Cardiovascular prophylaxis:** 75 mg to 100 mg once daily. Doses up to 325 mg once daily may be used in specific situations, but lower doses are generally preferred for chronic use.
* **Acute myocardial infarction:** 160 mg to 325 mg (chewable, non-enteric coated is preferred for rapid absorption in acute settings) as a loading dose, followed by 75 mg to 100 mg once daily.
* **Pain/Inflammation:** Dosing varies widely depending on the condition. Typical doses range from 325 mg to 650 mg every 4 to 6 hours as needed, not to exceed 4000 mg daily. (Enteric-coated formulations may not be ideal for acute pain relief due to delayed absorption).
* **Kawasaki disease:**
* **Acute phase:** 80 mg to 100 mg/kg/day divided into 4 doses.
* **Subacute phase (after fever subsides):** 3 mg/kg/day once daily.
## Pediatric Dosing
* **Kawasaki disease:**
* **Acute phase:** 80 mg to 100 mg/kg/day divided into 4 doses.
* **Subacute phase (after fever subsides):** 3 mg/kg/day once daily.
* **Pain/Inflammation:** Use in children for pain/inflammation is generally avoided due to the risk of Reye's syndrome, especially during viral illnesses. If absolutely necessary and no alternative exists, consult specific pediatric guidelines and monitor closely. Doses are typically weight-based and depend on the indication.
## Dose Adjustments
* No specific dose adjustment is typically required for renal or hepatic impairment, but caution is advised, particularly in severe impairment, due to potential for accumulation and increased risk of adverse effects.
## Contraindications
* Hypersensitivity to aspirin, salicylates, or NSAIDs.
* History of aspirin-induced asthma or urticaria.
* Active peptic ulceration or gastrointestinal bleeding.
* Children and teenagers with viral infections (influenza or chickenpox) due to the risk of Reye's syndrome.
* Severe hepatic or renal impairment.
* Certain bleeding disorders.
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, vomiting, abdominal pain, heartburn, occult bleeding, significant GI bleeding, ulceration.
* **Hematologic:** Increased bleeding time, bruising, petechiae, epistaxis, purpura.
* **Otic:** Tinnitus, hearing loss (especially at higher doses).
* **Allergic:** Urticaria, angioedema, bronchospasm, asthma exacerbation.
* **Other:** Headache, dizziness, confusion, metabolic acidosis (overdose).
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and COX-2 inhibitors:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Alcohol:** Increased risk of GI irritation and bleeding.
* **Methotrexate:** Aspirin can decrease methotrexate clearance, increasing toxicity.
* **Uricosuric agents (e.g., probenecid):** Aspirin antagonizes the uricosuric effect.
* **Antihypertensives:** Aspirin may reduce the effectiveness of some antihypertensive medications.
* **Valproic acid:** Aspirin can displace valproic acid from plasma protein binding sites, potentially increasing free valproic acid concentrations.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding (e.g., melena, hematemesis, bruising, prolonged bleeding from cuts).
* **GI Symptoms:** Assess for dyspepsia, abdominal pain, or other GI discomfort.
* **Renal Function:** Periodic assessment of renal function may be warranted, especially in patients with pre-existing renal disease or those on long-term, high-dose therapy.
* **Auditory Symptoms:** Monitor for tinnitus or hearing changes, which may indicate toxicity.
## Clinical Pearls
* The enteric coating delays absorption, making Ecospirin less suitable for rapid pain relief or in acute cardiovascular events where immediate antiplatelet effect is crucial (non-enteric coated chewable aspirin is preferred).
* While the enteric coating reduces gastric irritation, it does not eliminate the risk of GI bleeding or ulceration, particularly with chronic use or higher doses.
* Aspirin's antiplatelet effect is irreversible and lasts for the life of the platelet (7-10 days). Discontinuation before surgery requires careful consideration of bleeding risk and consultation with the surgeon.
* Reye's syndrome is a serious, potentially fatal condition associated with salicylate use in children and adolescents with viral infections. Avoid in this population.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the current prescribing information and relevant guidelines for complete and up-to-date details before making any treatment decisions.
